within Pharmacolibrary.Drugs.ATC.C;

model C01EA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.4666666666666667,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Alprostadil is a synthetic prostaglandin E1 (PGE1) used primarily for the treatment of erectile dysfunction and to maintain ductus arteriosus patency in newborns with specific congenital heart defects. It is approved and used today, typically administered via intracavernosal injection, intraurethral placement, or intravenous infusion in neonates.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult males following intravenous administration.</p><h4>References</h4><ol><li><p>Cawello, W, et al., &amp; Lomeli, AL (1995). Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. <i>British journal of clinical pharmacology</i> 40(3) 273–276. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1995.tb05784.x&quot;>10.1111/j.1365-2125.1995.tb05784.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8527291/&quot;>https://pubmed.ncbi.nlm.nih.gov/8527291</a></p></li><li><p>Cawello, W, et al., &amp; Seyberth, HW (1994). Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects. <i>European journal of clinical pharmacology</i> 46(3) 275–277. DOI:<a href=&quot;https://doi.org/10.1007/BF00192562&quot;>10.1007/BF00192562</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8070511/&quot;>https://pubmed.ncbi.nlm.nih.gov/8070511</a></p></li><li><p>Lin, X, et al., &amp; Tang, X (2009). Determination of alprostadil in rat plasma by ultra performance liquid chromatography-electrospray ionization-tandem mass spectrometry after intravenous administration. <i>Journal of pharmaceutical and biomedical analysis</i> 49(4) 983–988. DOI:<a href=&quot;https://doi.org/10.1016/j.jpba.2009.01.019&quot;>10.1016/j.jpba.2009.01.019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19217739/&quot;>https://pubmed.ncbi.nlm.nih.gov/19217739</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01EA01;
